Next-Gen Drug Discovery.
The premier conference series for life-science leaders, R&D directors, and AI scientists examining how machine intelligence is compressing discovery timelines, reshaping clinical trials, and unlocking precision medicine at population scale.
Date
14 October 2026
Venue
The ME Hotel
Format
In-person Panel Based Discussions
Series
World Pharma AI
2026
Inaugural Edition
500+
Senior Leaders
Global
Reach
The London Edition
Six focus areas, mapped to the decisions clinical and health-system leaders face right now.
Foundation models, generative chemistry, and ML-driven target identification compressing the path from hypothesis to candidate molecule.
Adaptive trial design, synthetic control arms, recruitment, and the operational AI reshaping how trials are run.
Multi-omics, biomarker discovery, and the AI translating genomic signal into targeted, individualised therapy.
Navigating FDA, EMA, and global frameworks for AI-enabled drug development, validation, and submission.
Harnessing real-world data, EHRs, and registries to generate evidence across the product lifecycle.
Predictive quality, process optimisation, and resilient pharmaceutical supply chains powered by machine learning.
Signal detection, adverse-event monitoring, and AI-augmented drug safety at scale.
Where capital, platforms, and AI-native biotech meet — the business of intelligent drug development.
Passes
Complimentary C-Suite Pass
Whos eligible?